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Neuronal ceroid lipofuscinoses (NCLs) comprise a heterogeneous group of metabolic storage diseases that
present with the accumulation of autoﬂuorescent lipopigment, neurodegeneration and premature death. Nine
genes have been thus far identiﬁed as the cause of different types of NCL, with ages at onset ranging from
around birth to adult, although the underlying etiology of the disease still remains elusive. We present a
family with typical NCL pathology in which we performed exome sequencing and identiﬁed a single homozy-
gous mutation in ATP13A2 that fully segregates with disease within the family. Mutations in ATP13A2 are a
known cause of Kufor–Rakeb syndrome (KRS), a rare parkinsonian phenotype with juvenile onset. These
data show that NCL and KRS may share etiological features and implicate the lysosomal pathway in
Parkinson’s disease.
INTRODUCTION
The neuronal ceroid lipofuscinoses (NCLs) are a heteroge-
neous group of inherited progressive degenerative diseases
that affect the brain and sometimes the retina. They are char-
acterized by lysosomal accumulation of autoﬂuorescent lipo-
pigment that display typical ultrastructural patterns (1).
There are now nine genes known to contain pathogenic muta-
tions causing NCL: CLN1 (PPT1 [MIM 256730]), CLN2
(TPP1 [MIM 204500]), CLN3 (MIM 204200), CLN4
(DNAJC5 (MIM 611203)), CLN5 (MIM 256731), CLN6
(MIM 601780), CLN7 (MFSD8 [MIM 610951]), CLN8
(MIM 600143), CLN10 (CTSD [MIM 610127]) that cause
onset at varying ages from birth to adulthood. Despite these
recent extraordinary advances in the identiﬁcation of causative
genes, the etiology of the disease remains elusive.
Recently, two reports (2,3) in the same dog model for a
late-onset NCL suggested that mutations in ATP13A2 might
be the cause of the disease in that animal. ATP13A2 belongs
to the P-type superfamily of ATPases that transport inorganic
cations and other substrates across cell membranes. It has pre-
viously been shown in humans that loss-of-function mutations
in ATP13A2 cause Kufor–Rakeb syndrome (KRS), a very rare
form of autosomal-recessive hereditary parkinsonism with de-
mentia and juvenile onset (4). The relationship between the
disease presented by the dog model of NCL and KRS is not
evident, as the clinical features of both diseases do not
appear to overlap signiﬁcantly. KRS typically presents with ri-
gidity, bradykinesia, spasticity, supranuclear upgaze paresis
and dementia. NCL disease varies according to the underlying
gene defect and severity of mutation, but typically includes
seizures, a progressive intellectual and motor deterioration,
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In addition, NCL shows autoﬂuorescent storage material with
typical ultrastructural patterns and in most juvenile onset cases
vacuolated lymphocytes (5). Brain magnetic resonance
imaging shows global atrophy for both syndromes, while
iron deposition is typically seen only in KRS.
Here, we present a large NCL family from Belgium (Fig. 1),
in which, although extensively studied in the past (6–8), no
mutation underlying the disease had been identiﬁed. The clin-
ical history of affected siblings is similar. All affected showed
difﬁculties in learning from around the ages of 8 years, with
vacuolated lymphocytes and ultrastructural pathology that
resembled that for NCL. The index case (II-1) had an unsteady
gait, myoclonus and mood disturbance from age 11 to 13, pro-
gressing to clear extrapyramidal involvement with akinesia
and rigidity, and dysarthric speech over the next 5 years. At
this point, the patient was found to be responsive to L-dopa,
but although considered, a diagnosis of young-onset Parkin-
son’s disease was not made. Interestingly, following L-dopa
administration, the patients developed dyskinesias something
that parallels what has been reported in KRS (9,10). At age
25, myoclonus was severe, speech was unintelligible, there
was loss of muscle strength, amyotrophy and the patient was
wheelchair bound. Neurological exam showed evidence of
pyramidal involvement, cerebellar ataxia and bulbar syndrome
(dysphonia, dysphagia and dysarthria). There was no apparent
retinal involvement, although the patient was reported to have
slow vertical ocular movements, which is also interesting
given the known occurrence of supranuclear gaze palsy with
upgaze restriction in KRS, and the patient eventually died at
age 36 of pulmonary emboli. Muscle biopsy showed numerous
subsarcolemmal autoﬂuorescence bodies with a ﬁngerprint ap-
pearance in electron microscopy and suggestion of neurogenic
muscular atrophy. Post-mortem pathological examination
showed abundant neuronal and glial lipofuscinosis involving
the cortex, basal nuclei, cerebellum, but sparing the white
matter, with whorled lamellar inclusions typical of NCL in
electron microscopy. Lipofuscin deposits were conﬁrmed in
the retina.
The additional three affected individuals in this kindred
showed a combination of progressive spinocerebellar ataxia,
bulbar syndrome, extrapyramidal and pyramidal involvement,
and intellectual deterioration (Table 1) [for additional clinical
details and ﬂudeoxyglucose-positron emission tomography
ﬁndings see (7,8)].
RESULTS
In this work, we identiﬁed a unique homozygous mutation in
ATP13A2 in a family with apparent autosomal-recessive ju-
venile onset NCL, using exome sequencing. We have, in add-
ition, tested other available NCL families with onset in the
juvenile or adult age range in which the genetic basis is
unknown for mutations in ATP13A2 (n ¼ 14), but have not
found further mutations. Nonetheless, the exome data, together
with previous reports in the dog model and in silico analysis of
the mutation, clearly show causality of this variant in
autosomal–recessive NCL.
From the cleaned set of results, generated from the exome
sequencing of three individuals, we excluded all the variants
that were not present in both affected siblings, and all the var-
iants shared by the unaffected individual. From this list, we
excluded all the synonymous variants, which led us to a
ﬁnal number of 25 variants (Supplementary Material,
Table S1). Of these, only one was shared in the homozygous
state in the affected individuals, c.T2429G in exon 22 of
ATP13A2. This predicts the missense change p.Met810Arg.
We also considered the hypothesis of compound heterozygous
mutations being the underlying cause of disease. However, we
did not identify compound heterozygous mutations that segre-
gated with the disease in these three individuals.
Having all the living members of this kindred available at
time of collection meant that we were able to verify segrega-
tion of the mutation in the family. We performed Sanger se-
quencing for exon 22 (RefSeq ID: NM_001141974) in all
Figure 1. Pedigree of the family studied. Pedigree showing complete segregation of p.M810R mutation in ATP13A2 in the available family members. T is the
reference allele, while G represents the mutation.
Table 1. Summary of the clinical descriptions of the affected individuals
Patients II-1 II-5 II-8 II-9
Gender Female Female Male Female
Age at onset 13 14 13 16
Age at examination 35 31 26 28
Rigidity +++ +++ + +
Akinesia +++ ++ +++ ++
Rest tremor ++ – – N/A
Dysarthria/dysphasia ++ + ++ +
Uncoordinated movements + – ++
Behavioural instability ++ – + –
Intellectual impairment ++ + + +
Response to levodopa +++ +++ ++ +
Adapted from (8).
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the family (Fig. 1).
No mutations have been reported in residue 810 in other
individuals with KRS or the dog model of NCL thus far; add-
itionally, this is a highly conserved residue in ATP13A2
(Fig. 2), mutation of this residue is absent from the most
recent single nucleotide polymorphism database (dbSNP)
(Build 135, which includes the latest 1000 Genomes data as
well as other large-scale population exome sequencing
studies, comprising a number in excess of 3000 individuals
with European ancestry and 1000 individuals with African an-
cestry) and both SIFT and PolyPhen2 attribute this variant
with a very high probability of being deleterious (SIFT score
is 0 while PolyPhen score is 1.000).
DISCUSSION
The vast majority of mutations in ATP13A2 associated with
KRS are truncating mutations arising by deletion, duplication,
insertion or splice site mutations (11), although there are two
reports of missense variants causing KRS (9,12). It is not yet
clear if there is a relationship between mutation type and
disease severity. The mechanism through which mutations in
ATP13A2 cause KRS is not fully understood, although it has
been previously shown that the wild-type protein is located
in the perimeter lysosomal membrane of transiently trans-
fected cells, while the unstable truncated mutants are retained
in the endoplasmic reticulum and degraded by the proteasome
(4). We have previously proposed a lysosomal pathway for
parkinsonism syndromes, centred around ceramide metabol-
ism, where we have hypothesized that ATP13A2 mutations
could be involved (13). Brieﬂy, following the discovery that
mutations in GBA, a gene known to cause the lysosomal
storage disease Gaucher’s disease, are also a risk factor for
Parkinson’s disease (PD), we hypothesized that ceramide me-
tabolism could play an important role in the pathogenesis of
PD. The link we proposed between ATP13A2 mutations and
ceramide metabolism, although not a direct one, was based
on the fact that ATP13A2 is a lysosomal transport protein
thought to be responsible for the maintenance of lysosomal
pH, where ceramide is metabolized. The hypothesis was
based on increased intracellular levels of ceramide, derived
from reduced activity of several proteins in the lysosomal
pathway. Among them were GBA, ATP13A2, PANK2 and
PLA2G6.
The implications of the present results are 2-fold: ﬁrst they
indicate that KRS and NCL, although separate clinical entities,
share etiology components; secondly, we provide further
support that a lysosomal pathway underlies the pathobiology
of another parkinsonism syndrome, in addition to the
Figure 2. Identiﬁcation of a homozygous mutation in ATP13A2. Figure showing the region on chromosome 1 where ATP13A2 is located, with the coverage and
variant calling obtained from exome sequencing at the p.M810R locus for one affected sibling. Also shown are Sanger sequencing traces for one affected and two
unaffected samples from the family and the protein sequence comparison displaying high conservation between species. The top panel on the chromatogram
shows the affected individual (homozygous G at the position), while the two bottom panels show unaffected individuals (one homozygous wild-type and
one heterozygous).
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(16)-linked diseases. Following the identiﬁcation of risk con-
ferring variability at GBA, which was conclusively demon-
strated to be the strongest risk factor known for PD,
identifying mutations in ATP13A2 in conﬁrmed NCL cases
undoubtedly corroborate the presence of parallels between
these two types of disorders. It is also interesting to note
that parkinsonism has previously been reported in NCL
disease families (17–21). Parkinson-like movement disorder
is always part of juvenile CLN3 disease (1). In fact, the fre-
quency of parkinsonian signs in NCL disease and the partial
phenotypic overlap between Kufor–Rakeb and NCL led
Farias and colleagues to predict that Kufor–Rakeb is an
NCL (3). Currently, there is no deﬁnitive pathological evi-
dence of this as no Kufor–Rakeb brain tissue is available
for the neuropathology study. However, biopsy analysis of a
sural nerve from one KRS patient revealed cytoplasmic inclu-
sions in Schwann cells and smooth muscle cells (22), which
may be interpreted as reminiscent of NCL inclusions. Further-
more, the brains of NCL patients caused by Cathepsin D deﬁ-
ciency (CLN10 disease) show intense a-synuclein staining
(23). Given the parallels between NCL and Parkinsonian dis-
orders, it was surprising that the Tibetan terriers with NCL
disease caused by ATP13A2 mutation did not present with
signs of parkinsonism (3). From these data, it is tempting to
propose that at least some cases of NCL disease and KRS
are two different clinical entities belonging to the same ethio-
logical disease spectrum, where ATP13A2 speciﬁcally and
lysosomal pathways, in general, play pivotal roles in the neu-
rodegenerative processes.
We propose that, in accordance with a new NCL classiﬁca-
tion scheme (1), the gene ATP13A2 should be linked to the
symbol CLN12.
In summary, we present conclusive evidence that mutations
in the parkinsonism gene ATP13A2 underlie a form of juvenile
NCL, suggesting not only that these two diseases share patho-
biological features, but also that KRS is indeed linked to the
lysosomal pathway, a feature that is becoming increasingly
evident for a variety of parkinsonian phenotypes.
MATERIALS AND METHODS
Exome sequencing was performed on three individuals from
this family: two affected (II-5, II-9) and an unaffected
sibling (II-4). The approach used assumed a recessive mode
of inheritance where shared variants could be determined in
the affected cases and subsequently ﬁltered out in the unaffect-
ed, while maintaining the number of sequencing runs to a
minimum. Genomic DNA was prepared according to Illumi-
na’s TruSeq Sample Preparation v3 (Illumina, CA, USA)
and capture was performed with Illumina’s TruSeq Exome En-
richment according to the manufacturer’s instructions. Se-
quencing was performed in Illumina’s HiSeq2000 using
100 bp paired-end reads.
Following quality-control procedures, samples yielded
between 7.1 and 8.5 Gb of high quality, aligned data. This
amount of data represented mean target coverage between
55.9–65.6×, percentages of targets covered at greater than
or equal to 10× of 88.9–90.6% and less than 1% of targets
not being covered at least once. Sequence alignment and
variant calling were performed against the reference human
genome (UCSC hg19) using bwa (24) and the Genome Ana-
lysis Toolkit (25). PCR duplicates were removed prior to
variant calling using the Picard software (http://picard.
sourceforge.net/index.shtml). Based on the hypothesis that
the mutation underlying this rare familial disease was not
present in the general population, we excluded all SNPs iden-
tiﬁed in the 1000 Genomes project (www.1000genomes.org/)
or in dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/,
Build 132). We thank the Rare NCL Gene Consortium for en-
couraging collaborative research on variant NCL cases, and
the families and physicians for providing samples.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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